+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Electronic Submissions to the FDA - eCTD Requirements - Webinar

  • ID: 4899711
  • Webinar
  • September 2018
  • Region: Global
  • 90 Minutes
  • Compliance Online
1 of 2
Why Should You Attend:

The US FDA and International Council on Harmonization (ICH) have been transitioning from the use of paper documents to use of the electronic Common technical Document (eCTD) for drug development programs. As of May 2018 the FDA no longer accepts paper submissions for investigational or marketing applications and requires documents for a drug development programs be provided in eCTD format. The eCTD is a structured format that standardizes the contents of applications and requires the use of XMLs for table of contents and hyper-linking of each document in an application. This format is designed for electronic viewing and seamless navigation of the application.

Attend this webinar to gain current, expert, and ‘practical application’ knowledge about the electronic Common Technical Document (eCTD) structure and requirements for electronic submissions. Basic instructions on executing an electronic submission, or efficiently working with a vendor who can make submissions on the company’s behalf, will be reviewed.

Areas Covered in the Webinar:

eCTD format and content
eCTD applicable and not applicable types of submissions
Summary of the requirements for electronic submissions
Preparing and filing an electronic IND application
Filing to an existing IND
Good submission practices
Common eCTD pitfalls
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Olga Pavlova, PhD, Regulatory Manager; Dr Pavlova is one of Amarex’s leading regulatory experts. She has written all sections of applications for IND, NDA, ANDA, BLA, IDE, PMA and ODD. Her experience includes writing IND submissions and regulatory documents; Investigator Brochures, annual reports, and clinical protocols. Dr Pavlova conducts gap analyses of product development programs which are then used to create FDA regulatory approval strategies in a wide range of therapeutic indications for small molecule drugs, biologics and devices. Before joining Amarex Dr. Pavlova gained experience in developing portfolio strategy, due diligence and invention marketing while doing an internship at The Center for Advancing Innovation, Inc. Dr Pavlova has over nine years of research experience in the area of molecular biology, microbiology and biochemistry.

Dr. Pavlova completed her graduate work at the Institute of Gene Biology, Russian Academy of Sciences and the Waksman Institute of Microbiology, Rutgers University, NJ and earned her PhD degree in Biology. She completed her postdoctoral work on food borne pathogenic bacteria virulence factor secretion at the National Institutes of Health, Bethesda, MD. She also earned her Masters degree in Biochemistry from the Moscow State University, Moscow, Russia.
Note: Product cover images may vary from those shown
Adroll
adroll